Conventional wisdom in the nootropic space frames cognitive enhancement and anxiolysis as opposing goals — you sharpen focus at the cost of calm, or you mute anxiety at the cost of drive. The preclinical literature on three Soviet-era research compounds tells a more nuanced story.

Semax (ACTH(4-7)PGP), Selank (a tuftsin-derived heptapeptide analogue), and Pinealon (the EDR tripeptide, Glu-Asp-Arg) were each developed through Russian and Ukrainian state research programs from the 1970s onward. They emerged from fundamentally different mechanistic hypotheses — Semax from neuropeptide analogues of adrenocorticotropin, Selank from immunomodulatory tuftsin derivatives, Pinealon from Khavinson’s short bioregulator work on the pineal gland. What the preclinical data now shows is that these three mechanisms — BDNF/TrkB upregulation, GABAergic-opioidergic anxiolysis, and epigenetic neuroprotection — are non-overlapping, and may be theoretically additive when the compounds are used together.

This post maps the mechanistic evidence behind each compound individually, examines the limited data on their combined use, and provides honest context on what the research cannot yet tell us. No human RCT data exists for this stack combination. Everything discussed here is preclinical. If you want the full compound profiles, start with Semax, Selank, and Pinealon individually. For the curated stack, see the Soviet Stack product page.

Background & Methods

The Three Compounds and What the Research Examined

Semax (ACTH(4-7)PGP / Met-Glu-His-Phe-Pro-Gly-Pro) is a synthetic heptapeptide analogue of the 4–10 fragment of adrenocorticotropin. Russian research groups, particularly at the Institute of Molecular Genetics in Moscow, have published extensively on its transcriptomic and neurochemical effects across ischemia, memory, and stress models since the 1990s. The bulk of the mechanistic literature uses rat transient middle cerebral artery occlusion (tMCAO) as a model of acute neurological injury, with a smaller body of work using cognitive behavioural paradigms in healthy rodents.

Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) is a synthetic analogue of the endogenous immunomodulatory tetrapeptide tuftsin, extended with a Pro-Gly-Pro C-terminal sequence to improve metabolic stability. Its anxiolytic profile has been characterised across multiple validated rodent models including the elevated plus maze (EPM), open field, and unpredictable chronic mild stress (UCMS) — the latter being the most translationally relevant model for generalised anxiety-like states. Doses in the published rodent literature range from 100 µg/kg to 300 µg/kg.

Pinealon (Glu-Asp-Arg / EDR) is a synthetic tripeptide identified by Professor Vladimir Khavinson’s group at the St. Petersburg Institute of Bioregulation and Gerontology. Research has used neuronal cell cultures (including cultures derived from transgenic Alzheimer’s and Huntington’s model animals), cerebellar neuron preparations, and in vivo rodent models to characterise its neuroprotective and epigenetic activity.

Three studies establish the mechanistic baseline used throughout this post:

1. Dolotov et al. (2006) used intranasal Semax at 50 µg/kg in rats to demonstrate BDNF/TrkB upregulation in hippocampus (PMID: 16996037).
2. Volkova et al. (2016) used real-time PCR to characterise Selank’s effects on 84 neurotransmission-related genes in rat frontal cortex (PMID: 26924987).
3. Khavinson et al. (2020) systematically reviewed EDR’s (Pinealon’s) molecular mechanisms in the context of neurodegeneration, identifying histone binding, MAPK/ERK modulation, and antioxidant enzyme upregulation as core pathways (PMID: 33396470).

Results & Mechanisms

Semax: BDNF, TrkB, and Transcriptomic Reach

The most-cited mechanistic dataset for Semax comes from Dolotov et al.’s 2006 paired studies. A single intranasal application at 50 µg/kg in rats produced a 1.4-fold increase in BDNF protein levels, a 1.6-fold increase in TrkB tyrosine phosphorylation, a 3-fold increase in exon III BDNF mRNA, and a 2-fold increase in TrkB mRNA in the hippocampus — all measured against saline controls (Dolotov et al., 2006, PMID: 16996037). The same research group demonstrated specific, high-affinity, calcium-dependent binding sites in rat basal forebrain (KD = 2.4 ± 1.0 nM; Bmax = 33.5 ± 7.9 fmol/mg protein), with BDNF upregulation confined to basal forebrain but absent in cerebellum — confirming regional specificity rather than nonspecific CNS flooding (Dolotov et al., 2006, PMID: 16635254).

The neuroinflammatory suppression data is equally specific. Dergunova et al. (2021) used quantitative RT-PCR in the rat tMCAO model to show Semax produced statistically significant decreases in Il1a, Il1b, Il6, Ccl3, and Cxcl2 mRNA — directly compensating for the pro-inflammatory gene expression pattern induced by ischemia-reperfusion (PMID: 34097675). At the protein level, Sudarkina et al. (2021) confirmed that Semax upregulates active CREB (a transcription factor central to synaptic plasticity and long-term memory formation) in subcortical structures while simultaneously downregulating MMP-9, c-Fos, and active JNK — markers of inflammation and apoptotic signalling (PMID: 34201112).

The transcriptomic reach is broad. RNA-Seq analysis by Filippenkov et al. (2020) identified 394 differentially expressed genes (>1.5-fold change) in Semax-treated vs. saline-treated ischemic rat brains at 24h — with Semax suppressing inflammation gene clusters and activating neurotransmission gene clusters in a pattern that directly counteracted the ischemia-induced transcriptomic disruption (PMID: 32580520). A 2025 update from the same group expanded this to approximately 2,000 differentially expressed genes normalised in frontal cortex, with neuroactive ligand-receptor interaction identified as the dominant shared pathway across brain regions (Filippenkov et al., 2025, PMID: 40650034).

The most recent in vivo evidence comes from a 2025 study in transgenic APPswe/PS1dE9/Blg mice — a validated model of amyloid pathology — in which Semax administration reduced the number of amyloid inclusions in both cortex and hippocampus while improving performance on open field, novel object recognition, and Barnes maze tests (Radchenko et al., 2025, PMID: 41479572).

Table 1 — Semax: Key Preclinical Findings

Selank: GABAergic, Opioidergic, and Monoaminergic Anxiolysis

Selank’s anxiolytic profile operates through at least three distinct molecular pathways, which is mechanistically unusual for a single compound and partly explains its separation from classic benzodiazepines in terms of side effect profile.

GABAergic allosteric modulation was characterised by Volkova et al. (2016) using real-time PCR in rat frontal cortex following 300 µg/kg administration. Selank altered the expression of 45 neurotransmission-related genes at 1h and 22 genes at 3h post-administration. A positive correlation was identified between the gene expression changes induced by Selank and those induced by GABA itself. Gene targets included major GABAA receptor subunits, GABA transporters, voltage-gated ion channels, dopamine receptors, and serotonin receptors — confirming that Selank acts at the level of GABAergic system gene regulation, not through simple GABA receptor agonism (Volkova et al., 2016, PMID: 26924987).

Enkephalinase inhibition represents a second, distinct pathway. Sokolov et al. (2002) demonstrated that Selank at 100 µg/kg produced an anxiolytic effect in the open field and increased the half-life of plasma leu-enkephalin in BALB/c mice by inhibiting enkephalin-degrading enzymes — effectively prolonging endogenous opioidergic anxiolytic signalling. Notably, this effect was strain-dependent and absent in C57Bl/6 mice, indicating phenotype-specific engagement of the opioidergic mechanism (Sokolov et al., 2002, PMID: 12432865).

Monoamine modulation was characterised by Narkevich et al. (2008) across hippocampus, hypothalamus, striatum, and frontal cortex in two inbred mouse strains with different anxiety phenotypes. Selank at 0.3 mg/kg consistently increased norepinephrine in hypothalamus in both strains. In stress-susceptible C57Bl/6 mice, it increased dopamine metabolites DOPAC and HVA in frontal cortex and hippocampus. In BALB/c mice (passive stress responders), it decreased 5-HT and 5-HIAA in hippocampus. The genotype-dependent directionality of these effects is interpreted as normalisation toward phenotype-specific homeostatic set points rather than uniform monoamine suppression (Narkevich et al., 2008, PMID: 19093364).

Under unpredictable chronic mild stress (UCMS) — arguably the most translationally relevant rodent anxiety model — Kasian et al. (2017) showed that Selank alone and Selank combined with diazepam both produced anxiolytic effects in the elevated plus maze, with the combination restoring anxiety indicators to pre-stress baseline levels. Individual Selank was most effective at reducing anxiety associated with chronic compound administration; the Selank-diazepam combination was superior specifically under UCMS conditions (Kasian et al., 2017, PMID: 28280289).

Critically, Slominsky et al. (2017) demonstrated in 6-hydroxydopamine-lesioned rats — a model of dopaminergic neuron loss — that Selank’s anxiolytic effect was preserved despite substantial nigrostriatal dopaminergic compromise, confirming that the anxiolytic mechanism operates independently of intact dopamine neurons (Slominsky et al., 2017, PMID: 28702721).

Pinealon (EDR): Epigenetic Neuroprotection and Structural Preservation

Pinealon’s active sequence is the EDR tripeptide (Glu-Asp-Arg). Its mechanism is categorically different from Semax and Selank — operating not on receptor binding or acute neurotransmitter modulation, but on epigenetic and transcriptional regulation at the cellular level.

Khavinson et al. (2020) characterised EDR’s molecular mechanisms in a comprehensive review: the tripeptide is proposed to enter cells and bind to histone proteins and/or RNA, thereby modifying MAPK/ERK signalling, influencing transcription factors PPARA and PPARG, and modulating serotonin and calmodulin levels. In neuronal cultures, EDR promoted synthesis of antioxidant enzymes SOD2 and GPX1, suppressed proapoptotic proteins caspase-3 and p53, and — critically — interfered with the elimination of dendritic spines in neuronal cultures derived from transgenic Alzheimer’s and Huntington’s model animals, preserving structural synaptic architecture (Khavinson et al., 2020, PMID: 33396470).

A 2022 review by Ilina, Khavinson et al. extended this framework, positioning EDR’s epigenetic action — via interaction with histone proteins, cis- and trans-regulatory DNA elements, and non-coding RNAs — as addressing multiple converging pathological processes including tau aggregation, mitochondrial dysfunction, oxidative stress, impaired energy metabolism, blood-brain barrier disruption, and neuroinflammation (Ilina et al., 2022, PMID: 35457077).

A key question for any orally or intranasally administered tripeptide is cellular bioavailability. Khavinson et al. (2022) systematically characterised the transport of ultrashort signalling molecules including EDR via POT family carriers (PEPT1, PEPT2, PHT1, PHT2) and LAT transporters (LAT1, LAT2). Molecular modelling confirmed LAT1’s capacity to transfer di- and tripeptides bidirectionally. The authors conclude that POT/LAT-mediated transport underlies the tissue specificity and geroprotective activity of EDR — providing a mechanistic basis for cellular uptake following systemic or mucosal delivery (Khavinson et al., 2022, PMID: 35887081). For broader context on bioregulator transport and oral bioavailability, see our Research Notes section.

Table 2 — Selank and Pinealon (EDR): Key Preclinical Findings

Stack-Level Mechanistic Complementarity

The rationale for combining these three research compounds is mechanistic non-overlap rather than additive dose intensity. Semax operates principally on BDNF/TrkB signalling, CREB activation, and transcriptome-level normalisation of neurotransmission gene expression. Selank operates on GABAergic allosteric modulation, enkephalinase inhibition, and phenotype-dependent monoamine regulation. Pinealon (EDR) operates on epigenetic gene regulation, antioxidant enzyme synthesis, and structural synaptic preservation.

There is one point of possible mechanistic interaction worth noting: both Semax and Selank show effects on GABAergic receptor binding. Vyunova et al. (2019) demonstrated that Semax modulates [³H]ACh and [³H]GABA receptor binding in a dose-dependent manner on rat neuronal plasma membranes (PMID: 31325343), while Volkova et al. (2016) established Selank’s GABAergic gene expression profile. Whether this represents complementary modulation at different regulatory levels or potential redundancy is unknown — no combination study has examined this directly.

The compounds in this stack have been studied individually for the mechanisms described above. The combination has not been studied directly in peer-reviewed literature.

For the full compound profiles and to explore the broader Research Compound Catalogue, see the individual pages for Semax, Selank, and Pinealon. For related stack designs, the Khavinson Triple pairs Pinealon with Epithalon and Semax in a longevity-oriented configuration, and the Longevity Stack covers the Epithalon and NAD+ axis. For cognitive compound comparisons across other mechanisms, see our Cognitive Compounds category.

Discussion & Limitations

The Soviet Stack preclinical dataset is — by research compound standards — unusually well-developed. The BDNF/TrkB quantification for Semax, the multi-gene GABAergic characterisation for Selank, and the transport mechanism work for Pinealon are all specific, reproducible, and cited across multiple independent research groups. This is meaningfully different from the situation with many research compounds where mechanism is inferred from behavioural data alone.

That said, the data has serious structural limitations that any honest analysis must confront.

Limitation 1: Predominantly rodent preclinical models, with no human RCT data.
The mechanistic studies described throughout this post use rat tMCAO ischemia models, inbred mouse strains (BALB/c and C57Bl/6), 6-OHDA parkinsonism models, and neuronal cell cultures. Generalisation of dose-response relationships, effect magnitudes, and specific gene expression outcomes to human neurobiology has not been established in controlled trials for any of the three compounds individually. The 3-fold BDNF mRNA increase seen with Semax in rat hippocampus, for example, tells us nothing definitive about the magnitude or duration of any equivalent effect in human neural tissue. Russian clinical literature does reference Semax and Selank use in human neurological contexts, but these publications have not been reproduced in Western peer-reviewed journals with randomised, placebo-controlled methodology.

Limitation 2: No combination (stack) studies exist in peer-reviewed literature.
Semax, Selank, and Pinealon have never been studied in combination in any published peer-reviewed research. All stack-level claims about mechanistic complementarity are inferences drawn from individually characterised pathways. Theoretical non-overlap does not guarantee additive benefit — it is equally possible that the combination produces unexpected interactions, that one compound modulates the bioavailability or receptor binding of another, or that the three mechanisms compete for shared downstream effectors. This is not a minor caveat — it is a fundamental gap in the evidence base.

Limitation 3: Semax and Selank transcriptomic data is primarily from pathological (ischemic or stress-lesioned) models, not healthy cognition.
Much of the Semax literature — particularly the RNA-Seq studies showing 394 and ~2,000 DEGs normalised — uses the tMCAO ischemia model. Whether the transcriptomic normalisation effect extrapolates to healthy neural tissue in the absence of pathological disruption is unclear. The cognitive enhancement signals in healthy rodents (novel object recognition, maze performance) are real, but the underlying mechanism in the non-pathological brain may differ substantially from the ischemia-reperfusion compensation mechanism that dominates the molecular data.

Limitation 4: Selank’s monoamine effects are phenotype-dependent and strain-specific.
The directionality of Selank’s monoaminergic effects — whether it increases or decreases DA metabolites and 5-HT — depends on the genetic background of the animal tested (Narkevich et al., 2008, PMID: 19093364). This phenotype-dependence is mechanistically interesting but renders simple extrapolation to heterogeneous human populations problematic. The human equivalent of an “anxiety phenotype” is not a controlled variable, and individual variation in response to Selank’s monoaminergic actions should be expected.

Limitation 5: Pinealon’s epigenetic mechanism is largely proposed rather than fully characterised.
The histone-binding and non-coding RNA modulation proposed for EDR in Ilina et al. (2022) is a mechanistic hypothesis supported by in vitro and molecular modelling data, not yet confirmed by direct chromatin immunoprecipitation or comprehensive epigenomic studies in vivo. The transport mechanism via PEPT1/PEPT2 and LAT1/LAT2 is better established, but the downstream epigenetic consequences of cellular EDR uptake in living neural tissue remain partially characterised.

What the data cannot yet tell us: optimal sequencing for the three compounds (concurrent vs. staggered administration), whether the GABAergic overlap between Semax and Selank is synergistic or redundant, and what the long-term transcriptomic consequences of combined use look like in any model system. These remain open research questions.

Conclusion

The preclinical case for the Soviet Stack rests on three mechanistically distinct, non-overlapping research compound profiles that individually represent some of the most well-characterised small-molecule neuroprotective agents in the Russian pharmacological literature.

Semax’s BDNF/TrkB upregulation in hippocampus — with the quantified 1.4×/1.6×/3×/2× fold changes across protein, phosphorylation, and mRNA endpoints — provides a concrete mechanism for its reported cognitive effects. Selank’s three-pathway anxiolytic profile (GABAergic allosteric modulation, enkephalinase inhibition, monoamine normalisation) explains why it does not appear to produce the tolerance and withdrawal characteristics of conventional GABA agonists. Pinealon’s epigenetic and structural neuroprotection layer — SOD2/GPX1 upregulation, dendritic spine preservation, MAPK/ERK modulation — operates on a longer time horizon than the other two compounds and may be best understood as infrastructure maintenance rather than acute performance enhancement.

For the self-optimiser using this as research context: the mechanistic rationale for the combination is stronger than for most stacks, because the three mechanisms genuinely do not appear to step on each other. The critical caveat is the complete absence of combination data — what we have is three individually characterised mechanisms and a plausible theoretical framework for why they might be additive. That is meaningfully different from demonstrated synergy.

The Soviet Stack ($245) is available in our Research Compound Catalogue. For protocols incorporating complementary longevity mechanisms, the Hallmarks Stack and Longevity Stack address adjacent pathways. All compounds are tested to HPLC-verified purity standards — see the Trust Layer below.

References

1. Radchenko AI et al. (2025). The Potential of the Peptide Drug Semax and Its Derivative for Correcting Pathological Impairments in the Animal Model of Alzheimer’s Disease. Acta Naturae. PMID: 41479572
2. Filippenkov IB et al. (2025). Genes That Associated with Action of ACTH-like Peptides with Neuroprotective Potential in Rat Brain Regions with Different Degrees of Ischemic Damage. International Journal of Molecular Sciences. PMID: 40650034
3. Sudarkina OY et al. (2021). Brain Protein Expression Profile Confirms the Protective Effect of the ACTH(4-7)PGP Peptide (Semax) in a Rat Model of Cerebral Ischemia-Reperfusion. International Journal of Molecular Sciences. PMID: 34201112
4. Filippenkov IB et al. (2020). Novel Insights into the Protective Properties of ACTH(4-7)PGP (Semax) Peptide at the Transcriptome Level Following Cerebral Ischaemia-Reperfusion in Rats. Genes. PMID: 32580520
5. Dergunova LV et al. (2021). The Peptide Drug ACTH(4-7)PGP (Semax) Suppresses mRNA Transcripts Encoding Proinflammatory Mediators Induced by Reversible Ischemia of the Rat Brain. Molekulyarnaya Biologiya. PMID: 34097675
6. Dolotov OV et al. (2006). Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus. Brain Research. PMID: 16996037
7. Dolotov OV et al. (2006). Semax, synthetic ACTH(4-10) analogue, binds specifically and increases levels of brain-derived neurotrophic factor protein in rat basal forebrain. Journal of Neurochemistry. PMID: 16635254
8. Glazova NY et al. (2021). Semax, synthetic ACTH(4-10) analogue, attenuates behavioural and neurochemical alterations following early-life fluvoxamine exposure in white rats. Neuropeptides. PMID: 33418449
9. Vyunova TV et al. (2019). An integrated approach to study the molecular aspects of regulatory peptides biological mechanism. Journal of Labelled Compounds and Radiopharmaceuticals. PMID: 31325343
10. Volkova A et al. (2016). Selank Administration Affects the Expression of Some Genes Involved in GABAergic Neurotransmission. Frontiers in Pharmacology. PMID: 26924987
11. Kasian A et al. (2017). Peptide Selank Enhances the Effect of Diazepam in Reducing Anxiety in Unpredictable Chronic Mild Stress Conditions in Rats. Behavioural Neurology. PMID: 28280289
12. Slominsky PA et al. (2017). Peptides Semax and Selank Affect the Behavior of Rats with 6-OHDA Induced PD-like Parkinsonism. Doklady Biological Sciences. PMID: 28702721
13. Narkevich VB et al. (2008). Effects of heptapeptide Selank on the content of monoamines and their metabolites in the brain of BALB/C and C57Bl/6 mice: a comparative study. Eksperimental’naya i Klinicheskaya Farmakologiya. PMID: 19093364
14. Sokolov OY et al. (2002). Effects of Selank on behavioral reactions and activities of plasma enkephalin-degrading enzymes in mice with different phenotypes of emotional and stress reactions. Bulletin of Experimental Biology and Medicine. PMID: 12432865
15. Khavinson V et al. (2020). EDR Peptide: Possible Mechanism of Gene Expression and Protein Synthesis Regulation Involved in the Pathogenesis of Alzheimer’s Disease. Molecules. PMID: 33396470
16. Ilina A, Khavinson V et al. (2022). Neuroepigenetic Mechanisms of Action of Ultrashort Peptides in Alzheimer’s Disease. International Journal of Molecular Sciences. PMID: 35457077
17. Khavinson V et al. (2022). Transport of Biologically Active Ultrashort Peptides Using POT and LAT Carriers. International Journal of Molecular Sciences. PMID: 35887081

About biohacker.team’s sourcing and quality standards: Every compound in the Soviet Stack — Semax, Selank, and Pinealon — is manufactured to research-grade specifications and verified by independent third-party HPLC analysis before dispatch. Certificates of Analysis (COAs) are available on request for every batch. Our supply chain is audited for sequence accuracy, purity (target ≥98%), and absence of endotoxin contamination. We do not sell research compounds without verified COA documentation. For full sourcing transparency, visit our About page or contact the team directly via our Contact page.

For research use only. Not for human consumption. Not intended to diagnose, treat, cure, or prevent any disease.